Overview

Tavo With Electroporation, Pembrolizumab, and Epacadostat in Patients With Unresectable Head and Neck Cancer

Status:
Active, not recruiting

Trial end date:
2024-05-31

Target enrollment:

Participant gender:

Summary

This phase II trial studies how well tavokinogene telseplasmid with electroporation, pembrolizumab, and epacadostat work in treating patients with squamous cell carcinoma of the head and neck that cannot be removed by surgery. Tavokinogene telseplasmid with electroporation is a gene therapy that may delay of tumor growth and which may have less toxicity than other methods of gene delivery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Epacadostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving tavokinogene telseplasmid with electroporation, pembrolizumab, and epacadostat may work better in treating squamous cell carcinoma of the head and neck.

Phase:

Phase 2

Details

Lead Sponsor:

Chase Heaton, MD
University of California, San Francisco

Collaborators:

Incyte Corporation
National Cancer Institute (NCI)
OncoSec Medical Incorporated

Treatments:

Pembrolizumab